Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 68 of 116

  1. R3767-ONC-2466

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  2. R4018-ONC-1721

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  3. RC48-ADC

    Chinese University of Hong Kong

    Muscle Invasive Bladder Carcinoma

    phase 2 small molecule active

    1 trial

  4. RD14-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 mab active

    1 trial

  5. REFRaME-P1

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  6. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  7. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  8. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  9. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  10. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. REGN5668

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  12. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  13. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. RELUGOLIX

    Fondazione Telethon ETS

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  15. REO 029

    ONCOLYTICS BIOTECH INC

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  16. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

    phase 2 mab completed

    1 trial

  17. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Pancreatic Adenocarcinoma

    phase 2 mab completed

    1 trial

  18. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  19. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Carcinoma, Non-small Cell Lung

    phase 2 mab completed

    1 trial

  20. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Osteosarcoma

    phase 2 mab completed

    1 trial

  21. REPRAB - MITO 36

    Fondazione Telethon ETS

    recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  22. REPRINT

    Fondazione Telethon ETS

    Collecting Duct Carcinoma, Medullary Renal cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. RESCUE-HUB

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  24. REVERSE

    Fondazione Telethon ETS

    Pseudomyxoma peritonei patients with high tumor burden.

    phase 2 small molecule active

    1 trial

  25. RITUXIMAB, Golcadomide

    Fondazione Telethon ETS

    Diffuse Large B-cells non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  26. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  27. RMC-4630

    Revolution Medicines

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  28. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  29. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  30. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  31. RMC-LUNG-101C

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  32. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  33. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  34. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  35. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  36. RX-3117

    Processa Pharmaceuticals

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  37. RX-3117

    Processa Pharmaceuticals

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  38. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  39. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  40. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  41. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  42. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  43. Radium-223 dichloride (Xofigo, BAY88-8223)

    Bayer HealthCare AG

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  44. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  45. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  46. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  47. Ramucirumab

    Eli Lilly and Company

    Gastric Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  48. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.